- Previous Close
8.56 - Open
0.00 - Bid 7.56 x --
- Ask 8.10 x --
- Day's Range
0.00 - 0.00 - 52 Week Range
0.00 - 14.45 - Volume
0 - Avg. Volume
2,832 - Market Cap (intraday)
156.784B - Beta (5Y Monthly) 1.18
- PE Ratio (TTM)
42.72 - EPS (TTM)
0.18 - Earnings Date Oct 24, 2024 - Oct 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
www.dexcom.comRecent News: D1EX34.SA
View MorePerformance Overview: D1EX34.SA
Trailing total returns as of 9/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: D1EX34.SA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: D1EX34.SA
View MoreValuation Measures
Market Cap
156.78B
Enterprise Value
153.82B
Trailing P/E
42.43
Forward P/E
32.89
PEG Ratio (5yr expected)
1.05
Price/Sales (ttm)
7.30
Price/Book (mrq)
11.25
Enterprise Value/Revenue
6.95
Enterprise Value/EBITDA
26.50
Financial Highlights
Profitability and Income Statement
Profit Margin
16.95%
Return on Assets (ttm)
6.26%
Return on Equity (ttm)
29.41%
Revenue (ttm)
3.93B
Net Income Avi to Common (ttm)
666.9M
Diluted EPS (ttm)
0.18
Balance Sheet and Cash Flow
Total Cash (mrq)
3.12B
Total Debt/Equity (mrq)
106.57%
Levered Free Cash Flow (ttm)
634.94M